FDA Clearance Tracker · P200015-S068
Edwards SAPIEN 3 Transcatheter Pulmonic Valve Delivery System
Last checked: Nov 20, 2026Latest source record: Jan 28, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jan 28, 2026
Approved
Time to decision
180 days
Received Aug 1, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
The decision
- FDA number
- P200015-S068
- Device name
- Edwards SAPIEN 3 Transcatheter Pulmonic Valve Delivery System
- Applicant
- Edwards Lifesciences, LLC
- Applicant location
- Irvine, CA
- Received
- Aug 1, 2025
- Decided
- Jan 28, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P200015
Device type
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for the next generation SAPIEN 3 pulmonic delivery system (models 9631PL20, 9631PL23, 9631PL26, and 9631PL29) and various updates to the Magnetic Resonance (MR) Safety information in the device labeling.
Source documents
Other decisions for Edwards Lifesciences, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PASCAL Precision Transcatheter Valve Repair SystemPMA supplement
P220003-S029 · Decided Oct 20, 2026 · 180 days after receipt · Panel Track
Device type: Tricuspid valve repair device, percutaneously delivered (NPS) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.